Update information

Update information

October 2017: A footnote was changed to update the information on UK marketing authorisations for entecavir.

January 2014: A correction has been made to the units used for abnormal alanine aminotransferase (ALT) in men and women. The abnormal ALT levels should read greater than or equal to 30 IU/L for males and greater than or equal to 19 IU/L for females, not IU/ml. This has been changed in recommendations 1.3.6, 1.3.7, 1.3.10, 1.5.3–5, 1.5.31, 1.6.1, 1.6.3–6, and 2.2.

June 2013: Recommendations 1.5.13 to 1.5.15 in this guideline update and replace recommendations 1.2 to 1.4 on the use of adefovir dipivoxil for treating chronic hepatitis B in Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (NICE technology appraisal guidance 96). NICE technology appraisal guidance 153, 154, 173 and recommendation 1.1 of NICE technology appraisal guidance 96 have been incorporated into this guideline and remain extant.

  • National Institute for Health and Care Excellence (NICE)